The BOHEMIA trial demonstrated a 26% reduction in new malaria infections following mass administration of ivermectin to children aged 5–15 in Kenya, complementing bed net use. Ivermectin’s mosquito-lethal properties target vectors feeding on treated persons, offering an adjunctive strategy amidst rising insecticide resistance. This represents the largest study of ivermectin for malaria control, supporting its integration into malaria elimination efforts in high-burden settings. Results were published in The New England Journal of Medicine, underpinning policy considerations for global public health interventions.